Jefferies on Alkermes (ALKS): 'We continue to think '2680 has a clean safety profile'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mail
Get Alerts ALKS Hot Sheet
Rating Summary:
16 Buy, 9 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
Jefferies analyst Akash Tewari reiterated a Buy rating and $41.00 price target on Alkermes (NASDAQ: ALKS).
The analyst comments "We found a paper investigating TAK-994's liver tox - The paper shows that '994's liver tox is due to reactive intermediates transiently formed during oxidative metabolism & not related to OX2. Overall, we think this further shows that '994's liver tox was related to its scaffold, which has limited read-across to ALKS-2680 & the class. We continue to think '2680 has a clean safety profile."
For an analyst ratings summary and ratings history on Alkermes click here. For more ratings news on Alkermes click here.
Shares of Alkermes closed at $31.19 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: just concluded a highly successful discussion with president Vladimir Putin
- Goodyear names Joe Hinrichs as board chairman
- Quantum Corporation CFO terminated, replaced by chief accounting officer
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & Co, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
